Pancreatic Cancer Research

Clinical trialPhase 1Unknown

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors

Recombinant Anti-EGFR Monoclonal Antibody(SCT200)in Patients With Advanced Solid Tumors or Lymphoma : A Phase Ⅰb, Open-label, Multicenter Study.

Outcome
Outcome unknown
Phase
Phase 1
Status
Unknown
Study type
Interventional
Start
30 September 2018
Listed end
30 April 2020
Enrollment
90 participants
Sites
1
Primary outcomes
Objective response rate (ORR)
Sponsor type
Industry
Results posted
No
Last update
2 October 2018

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody(SCT200)in patients with advanced solid tumors treated after failure of standard therapy.

Detailed description public domain (ClinicalTrials.gov)

This open label, multicenter phase Ib study is designed to evaluate Objective Response Rate (ORR) in advanced solid tumors (gastric/gastroesophageal junction cancer, hepatocellular carcinoma,pancreatic cancer,gallbladder cancer/bile duct cancer,renal cell carcinoma,ovarian cancer,or other advanced solid tumor) treated with anti-EGFR monoclonal antibody SCT200.